Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry
Ontology highlight
ABSTRACT: Lecanemab is a humanized immunoglobulin gamma 1 that is clinically approved for treating Alzheimer’s disease by binding to amyloid oligomers, protofibrils, and insoluble fibrils to clear Aβ aggregates in the brain. Although therapeutically effective, Lecanemab is associated with the side effect of amyloid-related imaging abnormalities. Besides, the antibody drugs are more prone to batch-to-batch quality variations due to impurities, oxidation, modifications and other potential factors. We have therefore performed the protein content analysis, the intact protein analysis, the N-glycoproteomics analysis of Lecanemab by LC-MS/MS or LC-MS. We also used MSfragger to search potential modifications on Lecanemab. The results provide molecular bases not only useful for studying the side effect of Lecanemab, but also for monitoring quality controls among different product batches. Here we provide the MS raw data and the searching results of LC-MS/MS, LC-MS, and the N-glycoproteomics analysis of Lecanemab.
ORGANISM(S): Homo Sapiens
SUBMITTER:
Bing Bai
PROVIDER: PXD066738 | iProX | Tue Jul 29 00:00:00 BST 2025
REPOSITORIES: iProX
ACCESS DATA